Next Generation Sequencing Facilitates Quantitative Analysis of CP5322-treated and Non-treated Transcriptomes in Kasumi-1 cells

Purpose: The goals of this study are designed to study the alteration of transcriptome profiling (RNA-seq) in CP5322-treated and non-treated cells. The drug was a herbal small molecular, which was designed as a HDAC inhibitor, called CP5322. TK1 was the group of CP5322-treated, and CK1 was the group of control. Methods: The mRNA profiles of drug-treated and non-treated cells were generated by next genenration sequencing, using Illumina platform. The clustering of the index-coded samples was performed on a cBot cluster generation system using HiSeq PE Cluster Kit v4-cBot-HS (Illumina) according to the manufacturer's instructions. After cluster generation, the libraries were sequenced on an Illumina platform and 150 bp paired-end reads were generated, which was called Raw Reads. And the low quality sequences and adaptor contamination were removed.Data processing was completed to obtain high-quality sequences (Clean Reads), and all subsequent analyses were based on Clean Reads. Results: Using the data analysis workflow, we mapped about 46 million sequence reads per sample to the human genome (h19) and identified 23 thousand transcripts in the drug-treated and non-treated cells. And the mapping rate was about 97%. RNA-seq data showed a significant alteration when the Kasumi-1 cells were treated by drug. Conclusions: The RNA-Seq data provided us a priori evidence for further research. The samples were designed as TK1 ( CP5322-treated group) and CK1 (non-treated group).The mRNA profiles of CP5322-treated and non-treated cells were generated by next genenration sequencing, using Illumina platform.